AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27928454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate supplementation (interdialytic doses)
Number of subjects: 63
Study 27928454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oral sodium bicarbonate supplementation, higher bicarbonate prescriptions in dialysis)
Number of subjects: 63
Study 27965790 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic oral nutritional supplement (ONS)
Number of subjects: 10
Study 27965790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional advice from a renal dietitian
Number of subjects: 10
Study 23613628 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (after diagnosis and before tumor progression)
Number of subjects: 110
Study 23613628 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression stages
Number of subjects: 110
Study 23613628 — intervention group
Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 110
Study 23613628 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression periods
Number of subjects: 110
Study 23613628 — intervention group
Group type: EXPERIMENTAL
Intervention: First progression period
Number of subjects: 110
Study 23613628 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression
Number of subjects: 110
Study 20384749 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fluence Q-switched Nd:YAG laser after 8 weeks of topical TC treatment
Number of subjects: 13
Study 20384749 — intervention group
Group type: COMPARATOR
Intervention: Topical triple combination (TC) cream
Number of subjects: 13
Study 17941095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) psychoeducational workshop
Number of subjects: 102
Study 17941095 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 102
Study 15916862 — intervention group
Group type: EXPERIMENTAL
Intervention: Web survey mode (n = 3500)
Number of subjects: 7000
Study 15916862 — intervention group
Group type: COMPARATOR
Intervention: Mail survey mode (n = 3500)
Number of subjects: 7000
Study 12590619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedating antidepressants (amitriptyline, imipramine, doxepin, mianserin)
Number of subjects: 10
Study 12590619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 10
Study 12590619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal doses of sedating antidepressants (dothiepin, mianserin, mirtazapine)
Number of subjects: 10
Study 12590619 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsedating antidepressants (moclobemide, fluoxetine, paroxetine, venlafaxine, nefazodone)
Number of subjects: 10
Study 12590619 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of nonsedating antidepressants and benzodiazepines
Number of subjects: 10
Study 12590619 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional tests of psychomotor performance or self‐ratings of side effects
Number of subjects: 10
Study 12590619 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants in clinical trials
Number of subjects: 10
Study 10683095 — intervention group
Group type: COMPARATOR
Intervention: Control drink (0.8 g x kg(‐1) body weight of glucose)
Number of subjects: 8
Study 10683095 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of glutamine)
Number of subjects: 8
Study 10683095 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of wheat hydrolysate)
Number of subjects: 8
Study 10683095 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate drink (0.8 g x kg(‐1) body weight of glucose + 0.3 g x kg(‐1) body weight of whey hydrolysate)
Number of subjects: 8
Study 8692117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus 5‐FU 600 mg/m2 plus folinic acid 300 mg/m2 day 2 to 4 with or without dipyridamole 3 x 75 mg p.o. day 1 to 5
Number of subjects: 174
Study 8692117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus 5‐FU 300 to 350 mg/m2, folinic acid 200 mg/m2 and interferon 5 x 10(9) U/m2 s.c. day 1 to 5
Number of subjects: 174
Study 8692117 — intervention group
Group type: EXPERIMENTAL
Intervention: PALA 250 mg/m2, MTX 250 mg/m2 day 1 and bolus FU 600 mg/m2 day 2 q day 14
Number of subjects: 174
Study 8692117 — intervention group
Group type: EXPERIMENTAL
Intervention: FU 2.6 g/m2 given as 24‐h infusion plus interferon 3 x 10(9) Ul s.c.
Number of subjects: 174
Study 8692117 — intervention group
Group type: EXPERIMENTAL
Intervention: FU 2.6 g/m2 given as 24‐h infusion, folinic acid 500 mg/m2 as 2‐h infusion with or without interferon 3 x 10(9) U s.c.
Number of subjects: 174
Study 8692117 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion regimens
Number of subjects: 174
Study 8692117 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus regimens
Number of subjects: 174
Study 1531467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal (IP) lidocaine + intraincisional bupivacaine
Number of subjects: 54
Study 1531467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraincisional bupivacaine
Number of subjects: 54
Study 1531467 — intervention group
Group type: COMPARATOR
Intervention: No additional drugs after general anesthesia (controls)
Number of subjects: 54
Study 6421472 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) and cis‐diamminedichloroplatinum(II) (AP)
Number of subjects: 45
Study 6421472 — intervention group
Group type: EXPERIMENTAL
Intervention: AP plus hexamethylmelamine (HAP)
Number of subjects: 45
Study 6421472 — intervention group
Group type: COMPARATOR
Intervention: Both regimens (AP and HAP)
Number of subjects: 45
Study 30975160 — intervention group
Group type: EXPERIMENTAL
Intervention: Call-handlers shown the degree-of-worry (DOW) on their screens
Number of subjects: 11413
Study 30975160 — intervention group
Group type: COMPARATOR
Intervention: Call-handlers not shown the degree-of-worry (DOW) on their screens
Number of subjects: 11413
Study 30365427 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-enhanced learning (TEL) intervention with online preworkshop MCQ test (no feedback) and postworkshop MCQ test (with feedback) after a 14-day delay.
Number of subjects: 186
Study 30365427 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no pre-/posttesting.
Number of subjects: 186
Study 30365427 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported changes in learning behavior, satisfaction, and efficiency of TEL.
Number of subjects: 186
Study 26934372 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization coverage surveys
Number of subjects: 1181
Study 26934372 — intervention group
Group type: EXPERIMENTAL
Intervention: Serologic biomarkers (IgG‐ELISA for tetanus antitoxin and Hib anti‐capsular titers)
Number of subjects: 1181
Study 24245805 — intervention group
Group type: EXPERIMENTAL
Intervention: UK Resilience Programme (UKRP)
Number of subjects: 2844
Study 24245805 — intervention group
Group type: COMPARATOR
Intervention: Usual school provision (control)
Number of subjects: 2844
Study 23281758 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine supplementation at 0.2%
Number of subjects: 576
Study 23281758 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine supplementation at 0.3%
Number of subjects: 576
Study 23281758 — intervention group
Group type: COMPARATOR
Intervention: Control group (0% L-threonine)
Number of subjects: 576
Study 19624730 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream with Bifidobacterium longum lysate at 10% (n = 33)
Number of subjects: 66
Study 19624730 — intervention group
Group type: COMPARATOR
Intervention: Control cream (n = 33)
Number of subjects: 66
Study 19624730 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream with Bifidobacterium longum lysate at 10%
Number of subjects: 66
Study 17435672 — intervention group
Group type: EXPERIMENTAL
Intervention: Microlaparoscopy
Number of subjects: 135
Study 17435672 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 135
Study 15279532 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-driven interventions
Number of subjects: 787
Study 15279532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic and TPB variables
Number of subjects: 787
Study 11378052 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) at doses of 300 mg, 600 mg, and 900 mg daily
Number of subjects: 376
Study 18370544 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50mg daily
Number of subjects: 100
Study 18370544 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4mg daily
Number of subjects: 100
Study 8157551 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 500 mg
Number of subjects: 12
Study 8157551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin 400 mg
Number of subjects: 12
Study 8157551 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg
Number of subjects: 12
Study 8157551 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ofloxacin 400 mg
Number of subjects: 12
Study 8157551 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 12
Study 8157551 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 12
Study 3410937 — intervention group
Group type: EXPERIMENTAL
Intervention: EE2 (100 ng/kg.day, orally)
Number of subjects: 39
Study 3410937 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.15 U/kg, sc, three times weekly)
Number of subjects: 39
Study 3410937 — intervention group
Group type: EXPERIMENTAL
Intervention: EE2 (50 ng/kg.day)
Number of subjects: 39
Study 3410937 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.09 U/kg, three times weekly)
Number of subjects: 39
Study 3410937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with EE2 (50 ng/kg.day) and GH (0.09 U/kg, three times weekly)
Number of subjects: 39
Study 3410937 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (0.15 U/kg, three times weekly) with EE2 (100 ng/kg.day)
Number of subjects: 39
Study 31822740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision training (generic or volleyball-specific motor actions)
Number of subjects: 51
Study 31822740 — intervention group
Group type: COMPARATOR
Intervention: Traditional volleyball training
Number of subjects: 51
Study 28252308 — intervention group
Group type: EXPERIMENTAL
Intervention: Utrogestan
Number of subjects: 111
Study 28252308 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8%
Number of subjects: 111
Study 29071946 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture plus western medicine
Number of subjects: 68
Study 29071946 — intervention group
Group type: COMPARATOR
Intervention: Western medicine only (Control)
Number of subjects: 68
Study 24148137 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based personalized feedback intervention
Number of subjects: 0
Study 24148137 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 0
Study 21983111 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Aspirin (C+A)
Number of subjects: 0
Study 21983111 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 19563287 — intervention group
Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap (SCPF)
Number of subjects: 17
Study 19563287 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 17
Study 17599602 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant nematode anticoagulant protein c2 (rNAPc2) administered intravenously every 48 hours for a total of 1 to 3 doses (1.5 to 10 microg/kg)
Number of subjects: 203
Study 17599602 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose rNAPc2 (≥7.5 microg/kg)
Number of subjects: 203
Study 17599602 — intervention group
Group type: COMPARATOR
Intervention: No UFH
Number of subjects: 203
Study 17599602 — intervention group
Group type: COMPARATOR
Intervention: Half-dose UFH
Number of subjects: 203
Study 15076785 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training alone (S)
Number of subjects: 31
Study 15076785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and endurance training (SE)
Number of subjects: 31
Study 15076785 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training alone (E)
Number of subjects: 31
Study 12269596 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a in RRMS (PRISMS trial)
Number of subjects: 532
Study 12269596 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a in SPMS (SPECTRIMS trial)
Number of subjects: 532
Study 12269596 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in RRMS
Number of subjects: 532
Study 12269596 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in SPMS
Number of subjects: 532
Study 10447151 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of caregivers (gender, support systems, relationship to patient)
Number of subjects: 0
Study 7797808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention diet (fat-reduced, oil-substituted diet with more fruits, vegetable soup, pulses, and crushed almonds and walnuts mixed with skim milk)
Number of subjects: 505
Study 7797808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention diet
Number of subjects: 505
Study 7797808 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 505
Study 2150640 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 to 5.0mg twice daily
Number of subjects: 800
Study 2150640 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 to 25mg twice daily
Number of subjects: 800
Study 533742 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tilt
Number of subjects: 5
Study 30829609 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy (SLNB)
Number of subjects: 200
Study 28627376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerogen Pro (PRO)
Number of subjects: 60
Study 28627376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerogen Solo (SOLO)
Number of subjects: 60
Study 28627376 — intervention group
Group type: EXPERIMENTAL
Intervention: NIVO vibrating mesh nebulizer
Number of subjects: 60
Study 28627376 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizers (JN)
Number of subjects: 60
Study 28627376 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler with AeroChamber‐MV (MDI‐AC)
Number of subjects: 60
Study 26064976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar
Number of subjects: 11
Study 26064976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 24347438 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 17
Study 24347438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22075163 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy (FFGT) Model
Number of subjects: 74
Study 19493182 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple mini-interview (MMI)
Number of subjects: 71
Study 17526456 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine + Amisulpride
Number of subjects: 56
Study 17526456 — intervention group
Group type: COMPARATOR
Intervention: Clozapine + Quetiapine
Number of subjects: 56
Study 15347773 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 mg twice daily for 3 months)
Number of subjects: 12
Study 15347773 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 adolescents without angiopathy and 8 healthy volunteers)
Number of subjects: 12
Study 11669433 — intervention group
Group type: COMPARATOR
Intervention: Air-filled cuffs
Number of subjects: 60
Study 11669433 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled water-filled cuffs
Number of subjects: 60
Study 9676083 — intervention group
Group type: EXPERIMENTAL
Intervention: Malstrom metal cup
Number of subjects: 90
Study 9676083 — intervention group
Group type: COMPARATOR
Intervention: silicone rubber cup
Number of subjects: 90
Study 7858934 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (Navoban)
Number of subjects: 630
Study 2789447 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 79
Study 2789447 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 79
Study 631012 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 0
Study 631012 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 0
Study 31111045 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative anti-inflammatory treatment (Cohort I)
Number of subjects: 120
Study 31111045 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative treatment (warming compress, lid hygiene, and anti-inflammatory treatment) and routine postoperative anti-inflammatory treatment (Cohort II)
Number of subjects: 120
Study 31111045 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced postoperative anti-inflammatory treatment (Cohort III)
Number of subjects: 120
Study 27260944 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (AB)
Number of subjects: 22
Study 27260944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal Vision Goggles (FVG)
Number of subjects: 22
Study 27260944 — intervention group
Group type: COMPARATOR
Intervention: Placebo Beverage (PB)
Number of subjects: 22
Study 27260944 — intervention group
Group type: COMPARATOR
Intervention: Placebo Goggles (PGs)
Number of subjects: 22
Study 27260944 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective Mood Ratings (AB and FVG)
Number of subjects: 22
Study 24919411 — intervention group
Group type: EXPERIMENTAL
Intervention: Motives for sports participation (achievement, health, social integration, fun and well-being)
Number of subjects: 121
Study 24919411 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline motives (achievement and fun and well-being)
Number of subjects: 121
Study 23639300 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Access to internet-based guided self-help program
Number of subjects: 66
Study 23639300 — intervention group
Group type: COMPARATOR
Intervention: 6-week Delayed Access condition
Number of subjects: 66
Study 16684261 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 542
Study 16684261 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no eradication)
Number of subjects: 542
Study 15156004 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pre-treatment (75 mg x 2 daily at least 48 hours before intervention)
Number of subjects: 50
Study 15156004 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel loading dose (300 mg at intervention time)
Number of subjects: 50
Study 10937544 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Number of subjects: 103
Study 10937544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic counseling
Number of subjects: 103
Study 10937544 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual supportive seminar
Number of subjects: 103
Study 10937544 — intervention group
Group type: EXPERIMENTAL
Intervention: Early‐stage day care
Number of subjects: 103
Study 10937544 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 103
Study 8871769 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 11
Study 8871769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1622057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender technique
Number of subjects: 120
Study 1622057 — intervention group
Group type: COMPARATOR
Intervention: DHS technique
Number of subjects: 120
Study 6721127 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (NA)
Number of subjects: 57
Study 6721127 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolept-analgesia (NLA)
Number of subjects: 57
Study 6721127 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridural anesthesia (PA)
Number of subjects: 57
Study 6721127 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 31596061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine with a loading dose of 1 μg/kg body weight followed by 0.2 μg/kg body weight/hour via continuous infusion
Number of subjects: 40
Study 31596061 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketamine 2 mg/kg body weight with atropine 0.01 mg/kg body weight
Number of subjects: 40
Study 28129985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant (5 mg, 10 mg, 20 mg, or 40 mg once daily)
Number of subjects: 106
Study 28129985 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 106
Study 28129985 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant
Number of subjects: 106
Study 28129985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 25084070 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/d
Number of subjects: 47
Study 25084070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 23884072 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with pegylated interferon (peg‐IFN) alfa‐2a plus self‐administered ribavirin (RBV)
Number of subjects: 66
Study 23884072 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with pegylated interferon (peg‐IFN) alfa‐2a plus self‐administered ribavirin (RBV)
Number of subjects: 66
Study 23884072 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (among those who received it)
Number of subjects: 66
Study 23884072 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants who received at least 1 dose of study medication
Number of subjects: 66
Study 20506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopically directed biopsies taken within 6 months of definitive therapy
Number of subjects: 737
Study 20506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Same day biopsies
Number of subjects: 737
Study 20506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy with one degree of variance
Number of subjects: 737
Study 20506504 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking more than one biopsy
Number of subjects: 737